Associated Papers
The use of genistein and ambroxol may be an effective approach in correcting cellular dysfunctions of mucopolysaccharidosis-plus syndrome.
Cyske Z et al.
Mammalian Genome : Official Journal of the International Mammalian Genome Society, 2025
Mucopolysaccharidoses-What Clinicians Need to Know: A Clinical, Biochemical, and Molecular Overview.
Lipiński P et al.
Biomolecules, 2025
Impaired biogenesis of renin granules in juxtaglomerular cells of Vps33a (D251E) mutant mice.
Wang H et al.
Journal of Cell Science, 2025
Triclabendazole suppresses cellular levels of glycosaminoglycan-A potential therapeutic agent for mucopolysaccharidoses and related diseases.
Terawaki S et al.
Iscience, 2025
Cellular and molecular changes in mucopolysaccharidosis-plus syndrome caused by a homozygous c.599G > C (p.Arg200Pro) variant of the VPS33A gene.
Cyske Z et al.
Journal of Applied Genetics, 2025
Mucopolysaccharidosis-Plus Syndrome: Is This a Type of Mucopolysaccharidosis or a Separate Kind of Metabolic Disease?
Cyske Z et al.
International Journal of Molecular Sciences, 2024
Prenatal Diagnosis of Mucopolysaccharidosis-Plus Syndrome (MPSPS).
Sofronova V et al.
Genes, 2023
Juvenile mucopolysaccharidosis plus disease caused by a missense mutation in VPS33A.
Pavlova EV et al.
Human Mutation, 2022
Mucopolysaccharidosis-Plus Syndrome: Report on a Polish Patient with a Novel VPS33A Variant with Comparison with Other Described Patients.
Lipiński P et al.
International Journal of Molecular Sciences, 2022
Select a paper to view details